Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Colistin (Polymyxin E) Injectable bulk supplier for pharma manufacturers

Colistin (Polymyxin E) Injectable Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV/IM/SC)

Available Strengths: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Reference Brands: Coly-Mycin M(US)

Category: Antibiotics

Colistin (Polymyxin E) disrupts bacterial cell membrane integrity by binding to lipopolysaccharides, causing bacterial lysis. It is effective against multidrug-resistant Gram-negative bacteria. Benefits include rapid bactericidal activity, crucial in severe infections like pneumonia and sepsis, especially when other antibiotics fail, making it vital for resistant infection management.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Colistin (Polymyxin E) is approved in the EU and US for severe, multidrug-resistant Gram-negative bacterial infections. In the EU, brands like Colistin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and safety monitoring. Due to its critical role in combating resistant infections, strict prescribing, storage, and administration regulations are enforced. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We support seamless market access while ensuring adherence to European and US standards.

Colistin (Polymyxin E) Injectable — third party manufacturing & bulk supply

Colistin (Polymyxin E) Injectable is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Colistin (Polymyxin E) Injectable is supplied as Injectable (IV/IM/SC) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Colistin (Polymyxin E) Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Colistin (Polymyxin E) Injectable →
Back to Listing

Frequently Asked Questions

Colistin (Polymyxin E) Injectable is listed as Injectable (IV/IM/SC) in 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Colistin (Polymyxin E) Injectable is referenced against Coly-Mycin M(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Rifaximin

Strength:
100 mg/5 mL, 200 mg, 550 mg

Form: Tablet / Oral Suspension

Reference Brands: Xifaxan (USA), Targaxan (EU), Normix (LATAM)

View Details
Ceftaroline

Strength:
600 mg

Form: Injection

Reference Brands: Teflaro (USA), Zinforo (EU)

View Details
Secnidazole

Strength:
2 g

Form: Oral granules/ tablets

Reference Brands: Solosec (USA)

View Details
Omaveloxolone

Strength:
150 mg

Form: Tablets

Reference Brands: Skyclarys (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.